声动力疗法（SDT）作为一种有前途的新型非侵入性脑肿瘤治疗方法而受到关注，它能够靶向并选择性杀死肿瘤细胞，且副作用有限。本综述探讨了 SDT 的机制以及正在进行的临床试验，旨在优化超声处理参数以潜在治疗胶质母细胞瘤 (GBM) 和弥漫性内质性脑桥胶质瘤 (DIPG)。简要讨论了 Mayo Clinic 治疗的第一例复发性 GBM 患者的结果。这篇文献综述的作者使用了包括 PubMed、EMBASE 和 OVID 在内的电子数据库。通过搜索文本单词/短语和 MeSH 术语来识别报告相关临床前和临床试验的文章，包括以下内容：“声动力疗法”、“SDT”、“聚焦超声”、“5-ALA”、“ALA”、“大脑”肿瘤”、“弥漫性脑桥神经胶质瘤”、“胶质母细胞瘤”和“高级别神经胶质瘤”。对研究 SDT 在脑肿瘤中具体应用的临床前和临床试验进行了回顾。在高级神经胶质瘤和 GBM 的临床前模型中，SDT 已显示出通过产生活性氧来靶向肿瘤细胞死亡的证据。复发性 GBM 和 DIPG 的新临床试验结果显示，治疗反应成功，招募的患者所经历的副作用最小。迄今为止，SDT 已被证明是一种有前途的非侵入性癌症治疗方法，患者耐受性良好。作者提供的初步数据表明 GBM 对单次 SDT 治疗有良好的放射学反应，未发表的观察结果表明，即使在多次（每月）超声处理门诊治疗后也没有脱靶效应。 SDT临床试验的范围是研究它是否可以成为将GBM或DIPG的致命诊断转化为慢性、可治疗疾病的手段。SDT比化疗和化疗更安全、可重复且耐受性更好。放射治疗。它已被证明对人类癌症治疗有效，但需要更多的临床试验来建立声敏剂输送、治疗参数和联合疗法的标准化方案。最合适的治疗时机也有待确定——是预防术后复发，还是作为不适合重做手术的复发性 GBM 患者的挽救选择。希望SDT也能开发用于更广泛的临床适应症，例如转移瘤、脑膜瘤和低级别胶质瘤。进一步的临床试验正在准备中。

Sonodynamic therapy (SDT) is gaining attention as a promising new noninvasive brain tumor treatment that targets and selectively kills tumor cells, with limited side effects. This review examines the mechanisms of SDT and ongoing clinical trials looking at optimization of sonication parameters for potential treatment of glioblastoma (GBM) and diffuse intrinsic pontine glioma (DIPG). The results in the first patient with recurrent GBM treated at the Mayo Clinic are briefly discussed.The authors of this literature review used electronic databases including PubMed, EMBASE, and OVID. Articles reporting relevant preclinical and clinical trials were identified by searching for text words/phrases and MeSH terms, including the following: "sonodynamic therapy," "SDT," "focused ultrasound," "5-ALA," "ALA," "brain tumors," "diffuse pontine glioma," "glioblastoma," and "high grade glioma."Preclinical and clinical trials investigating the specific use of SDT in brain tumors were reviewed. In preclinical models of high-grade glioma and GBM, SDT has shown evidence of targeted tumor cell death via the production of reactive oxygen species. Emerging clinical trial results within recurrent GBM and DIPG show evidence of successful treatment response, with minimal side effects experienced by recruited patients. So far, SDT has been shown to be a promising noninvasive cancer treatment that is well tolerated by patients. The authors present pilot data suggesting good radiological response of GBM to a single SDT treatment, with unpublished observation of a lack of off-target effects even after multiple (monthly) sonication outpatient treatments. The scope of the clinical trials of SDT is to investigate whether it can be the means by which the fatal diagnosis of GBM or DIPG is converted into that of a chronic, treatable disease.SDT is safe, repeatable, and better tolerated than both chemotherapy and radiotherapy. It has been shown to have an effect in human cancer therapy, but more clinical trials are needed to establish standardized protocols for sonosensitizer delivery, treatment parameters, and combination therapies. The most appropriate timing of treatment also remains to be determined-whether to prevent recurrence in the postoperative period, or as a salvage option in patients with recurrent GBM for which redo surgery is inappropriate. It is hoped that SDT will also be developed for a wider spectrum of clinical indications, such as metastases, meningioma, and low-grade glioma. Further clinical trials are in preparation.